Abstract: 2-(2'-Naphthyl) acetaldehyde derivatives optionally substituted at the 2 position and/or positions C-1',4',5',7' or 8'; and/or position C-6' or positions C-5' and 7' exhibit anti-inflammatory, analgesic, antipyretic and anti-pruritic activity.

Abstract: Novel 8R-antimeric and racemic 11.alpha.-methylsubstituted-prosta-5-cis, 13-trans-dienoic and prost-13-trans-enoic acids having oxygenated functions at the C-9 and C-15 positions of the molecule, as well as the 15-methyl or ethyl derivatives thereof and processes for making such compounds. Also encompassed are the pharmaceutically acceptable, non-toxic alkyl esters and salts of the carboxylic acid function of these novel compounds.

Abstract: Process for degrading the glycoside neriifolin and its acetate to the cardenolide digitoxigenin. Novel intermediates are also described.

Abstract: This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.

Abstract: Novel process for the preparation of 11.alpha.-hydroxymethyl derivatives of natural (8R-) and racemic 9-keto-15.alpha.-hydroxy- and 9,15.alpha.-dihydroxy-prosta-5-cis,13-trans-dienoic and prost-13-transenoic acids, and the novel 15-methyl and ethyl substituted derivatives thereof, as well as the esters of the primary and secondary hydroxy groups and the non-toxic, pharmaceutically acceptable salts of the novel compounds.

Abstract: 10.alpha.-Hydroxy-11-desoxy-prostaglandin analogs of the PGE.sub.1 and PGE.sub.2 and PGF.sub.1.sub..alpha. and PGF.sub.2.sub..alpha. series, the 11-dehydro derivatives thereof as well as the 9,10-ketals in the PGF series, and methods of preparing same, 9-keto-10.alpha.,15.alpha.-dihydroxyprosta-13-trans-enoic or 5-cis,13-trans-dienoic acid, 9.alpha.,10.alpha.,15.alpha.-trihydroxyprosta-11,13-trans-dienoic or 5-cis, 11,13-trans-trienoic acid and 9.alpha.,10.alpha.-isopropyli-denedioxy-15.alpha.-hydroxyprosta-13-trans-e noic or 5-cis,13-trans-dienoic acid are representative of the class. Also included are the corresponding pharmaceutically acceptable, non-toxic esters, ethers and salts. These compounds possess prostaglandin-like activity and thus are useful in the treatment of mammals, where prostaglandins are indicated.